EyePoint Pharmaceuticals (EYPT) News Today → The Worst is Yet to Come… (From Porter & Company) (Ad) Free EYPT Stock Alerts $10.71 -0.04 (-0.37%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 1:42 AM | americanbankingnews.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Buy" by BrokeragesJune 1 at 1:39 AM | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by AnalystsShares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have been assigned a consensus recommendation of "Buy" from the seven analysts that are covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price tarMay 30 at 7:42 AM | americanbankingnews.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down to $11.16May 29, 2024 | marketbeat.comMonashee Investment Management LLC Takes $4.04 Million Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Monashee Investment Management LLC bought a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 175,000 shares of the company's stock, vaMay 29, 2024 | finance.yahoo.comInvesting in EyePoint Pharmaceuticals (NASDAQ:EYPT) a year ago would have delivered you a 91% gainMay 24, 2024 | marketbeat.comFranklin Resources Inc. Has $107.25 Million Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Franklin Resources Inc. boosted its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 11.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,640,651 shares of the comMay 17, 2024 | insidertrades.comDavid R. Guyer Sells 11,625 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) StockMay 17, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 3.8% Following Insider SellingEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 3.8% on Insider SellingMay 17, 2024 | finance.yahoo.comInsider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)May 16, 2024 | globenewswire.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 15, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 5.5%EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 5.5%May 15, 2024 | marketbeat.com317,010 Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Purchased by First Turn Management LLCFirst Turn Management LLC acquired a new stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 317,010 shares of the company's stock, valued at approMay 15, 2024 | marketbeat.comQ2 2024 Earnings Estimate for EyePoint Pharmaceuticals, Inc. Issued By HC Wainwright (NASDAQ:EYPT)EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Analysts at HC Wainwright decreased their Q2 2024 earnings per share (EPS) estimates for EyePoint Pharmaceuticals in a research report issued on Monday, May 13th. HC Wainwright analyst Y. Chen now anticipates that the company will postMay 14, 2024 | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Expected to Earn Q1 2025 Earnings of ($0.49) Per ShareEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings estimates for EyePoint Pharmaceuticals in a note issued to investors on Monday, May 13th. HC Wainwright analyst Y. Chen forecasts that the company will earn ($0.49) per share for tMay 13, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals: Maintaining Buy Rating Amidst Progress and TrialsMay 13, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Given New $30.00 Price Target at HC WainwrightHC Wainwright cut their target price on shares of EyePoint Pharmaceuticals from $33.00 to $30.00 and set a "buy" rating on the stock in a research note on Monday.May 10, 2024 | finance.yahoo.comEyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite ChallengesMay 9, 2024 | insidertrades.comInsider Buying: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Major Shareholder Acquires $10,081,000.00 in StockMay 8, 2024 | marketbeat.comInsider Buying: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Major Shareholder Buys 850,000 Shares of StockEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) major shareholder Cormorant Asset Management, Lp acquired 850,000 shares of the stock in a transaction dated Monday, May 6th. The shares were bought at an average cost of $11.86 per share, for a total transaction of $10,081,000.00. Following the acquisition, the insider now owns 8,325,000 shares in the company, valued at approximately $98,734,500. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.May 8, 2024 | investorplace.comEYPT Stock Earnings: EyePoint Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024May 8, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) PT Lowered to $38.00Robert W. Baird cut their price target on EyePoint Pharmaceuticals from $46.00 to $38.00 and set an "outperform" rating for the company in a report on Wednesday.May 8, 2024 | globenewswire.comEyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate DevelopmentsMay 7, 2024 | markets.businessinsider.comMaintaining Buy Rating on EyePoint Pharmaceuticals Despite P2 Study SetbackMay 7, 2024 | seekingalpha.comEyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead ProgramMay 7, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Given New $28.00 Price Target at Chardan CapitalChardan Capital decreased their target price on EyePoint Pharmaceuticals from $39.00 to $28.00 and set a "buy" rating on the stock in a report on Tuesday.May 7, 2024 | markets.businessinsider.comMaintaining Buy Rating on EyePoint Pharmaceuticals: Strong Prospects in wAMD Market Despite NPDR Study SetbackMay 6, 2024 | msn.comEyePoint tumbles 30% premarket on failed Phase 2 studyMay 6, 2024 | seekingalpha.comEyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)May 6, 2024 | finance.yahoo.comWhy Is EyePoint Pharmaceuticals Stock Plummeting On Monday?May 6, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down to $19.74EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down to $19.74May 6, 2024 | marketbeat.comTrading was temporarily halted for "EYPT" at 09:05 AM with a stated reason of "LULD pause."May 6, 2024 | marketbeat.comTrading was temporarily halted for "EYPT" at 06:05 AM with a stated reason of "News pending."May 6, 2024 | globenewswire.comEyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic RetinopathyApril 29, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 5.9%EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 5.9%April 28, 2024 | 247wallst.comThese Biotechs and IPOs Inspire Big Insider BuyingApril 25, 2024 | marketbeat.comJennison Associates LLC Takes Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Jennison Associates LLC acquired a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,066,240 shares of the company's stock, valued at approximately $2April 24, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 6.6% EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 6.6%April 23, 2024 | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stock Position Lifted by Federated Hermes Inc.Federated Hermes Inc. grew its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 194.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 674,824 shares of the company's stock after acquiring an additioApril 23, 2024 | insidertrades.comInsider Buying: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Major Shareholder Buys 581,765 Shares of StockApril 22, 2024 | marketbeat.comCormorant Asset Management, Lp Buys 581,765 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) StockEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) major shareholder Cormorant Asset Management, Lp bought 581,765 shares of the business's stock in a transaction on Thursday, April 18th. The stock was purchased at an average price of $18.03 per share, with a total value of $10,489,222.95. Following the completion of the transaction, the insider now directly owns 7,475,000 shares of the company's stock, valued at $134,774,250. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.April 20, 2024 | msn.comVeru, EyePoint Pharmaceuticals, Sintx Technologies among healthcare moversApril 19, 2024 | markets.businessinsider.comBuy Recommendation: EyePoint Pharmaceuticals’ Promising Outlook with EYP-1901 for Diabetic Retinopathy and AMDApril 18, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Sees Strong Trading VolumeEyePoint Pharmaceuticals (NASDAQ:EYPT) Sees Unusually-High Trading VolumeApril 16, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 2%EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 2% HigherApril 16, 2024 | globenewswire.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 15, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 5.7%EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 5.7%April 15, 2024 | marketbeat.com35,000 Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Purchased by DekaBank Deutsche GirozentraleDekaBank Deutsche Girozentrale acquired a new position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 35,000 shares of the company's stock, valued at approximately $820April 13, 2024 | markets.businessinsider.comStrong Buy Rating for EyePoint Pharmaceuticals Amid Promising Developments in Ophthalmic TherapiesApril 12, 2024 | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of "Buy" from AnalystsShares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have received an average recommendation of "Buy" from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 1-year priceApril 2, 2024 | globenewswire.comEyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address What is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners” (Ad)A small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.” Click here to find out who they are. EYPT Media Mentions By Week EYPT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EYPT News Sentiment▼0.640.76▲Average Medical News Sentiment EYPT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EYPT Articles This Week▼74▲EYPT Articles Average Week Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LAB News CTKB News QTRX News PACB News NAUT News HBIO News SEER News AKYA News BNGO News PRE News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EYPT) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
